{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:24:30Z","timestamp":1740108270370,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EffRx Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00198-020-05802-5","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T15:23:43Z","timestamp":1610637823000},"page":"595-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-9258","authenticated-orcid":false,"given":"M.","family":"Hiligsmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"issue":"1","key":"5802_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstrom","year":"2020","unstructured":"Borgstrom F, Karlsson L, Ortsater G, Norton N, Halbout P, Cooper C et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15(1):59","journal-title":"Arch Osteoporos"},{"issue":"1","key":"5802_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40520-018-1109-4","volume":"31","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O et al (2019) Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res 31(1):15\u201317","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"5802_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691\u2013705","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"5802_CR4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00198-019-05104-5","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al-Daghri N, Biver E et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 30(11):2155\u20132165","journal-title":"Osteoporos Int"},{"issue":"3","key":"5802_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00223-009-9329-4","volume":"86","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202\u2013210","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"5802_CR6","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","volume":"29","author":"CT Yeam","year":"2018","unstructured":"Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29(12):2623\u20132637","journal-title":"Osteoporos Int"},{"issue":"1","key":"5802_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00198-011-1791-y","volume":"23","author":"MR McClung","year":"2012","unstructured":"McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL et al (2012) Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int 23(1):267\u2013276","journal-title":"Osteoporos Int"},{"issue":"1-2","key":"5802_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijpharm.2012.04.073","volume":"432","author":"LA Hodges","year":"2012","unstructured":"Hodges LA, Connolly SM, Winter J, Schmidt T, Stevens HN, Hayward M et al (2012) Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int J Pharm 432(1-2):57\u201362","journal-title":"Int J Pharm"},{"issue":"2","key":"5802_CR9","first-page":"S253","volume":"30","author":"P Fardellone","year":"2019","unstructured":"Fardellone P, Bo\u00ebzennec B, Cortet B (2019) Upper gastrointestinal safety with the buffered solution of alendronate 70 mg: 6 years of post-marketing experience. Osteoporos Int 30(2):S253\u2013S773","journal-title":"Osteoporos Int"},{"issue":"3","key":"5802_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","volume":"33","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33(3):205\u2013224","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"5802_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, al-Daghri N, Bruy\u00e8re O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30(1):45\u201357","journal-title":"Osteoporos Int"},{"issue":"2","key":"5802_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D et al (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 16(2):e1\u2013e5","journal-title":"Value Health"},{"issue":"3","key":"5802_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00198-018-04821-7","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY (2019) Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporos Int 30(3):649\u2013658","journal-title":"Osteoporos Int"},{"issue":"2","key":"5802_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","volume":"49","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2019) Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum 49(2):184\u2013196","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"5802_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.semarthrit.2020.02.004","volume":"50","author":"M Hiligsmann","year":"2020","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. Semin Arthritis Rheum 50(3):394\u2013400","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"5802_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1524-4733.2008.00497.x","volume":"12","author":"M Hiligsmann","year":"2009","unstructured":"Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12(5):687\u2013696","journal-title":"Value Health"},{"key":"5802_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","volume":"8","author":"A Svedbom","year":"2013","unstructured":"Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8:137","journal-title":"Arch Osteoporos"},{"key":"5802_CR18","doi-asserted-by":"crossref","unstructured":"Unim B et al (2020) Trends in hip and distal femoral fracture rates in Italy from 2007 to 2017. Bone","DOI":"10.1016\/j.bone.2020.115752"},{"issue":"3","key":"5802_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00198-012-2021-y","volume":"24","author":"P Piscitelli","year":"2013","unstructured":"Piscitelli P, Chitano G, Johannson H, Brandi ML, Kanis JA, Black DM (2013) Updated fracture incidence rates for the Italian version of FRAX(R). Osteoporos Int 24(3):859\u2013866","journal-title":"Osteoporos Int"},{"issue":"3","key":"5802_CR20","first-page":"54","volume":"8","author":"P Piscitelli","year":"2011","unstructured":"Piscitelli P, Tarantino U, Chitano G, Argentiero A, Neglia C, Agnello N, Saturnino L, Feola M, Celi M, Raho C, Distante A, Brandi ML (2011) Updated incidence rates of fragility fractures in Italy: extension study 2002-2008. Clin Cases Miner Bone Metab 8(3):54\u201361","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"2","key":"5802_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375\u2013382","journal-title":"Bone"},{"issue":"5","key":"5802_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S8756-3282(00)00381-1","volume":"27","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27(5):585\u2013590","journal-title":"Bone"},{"issue":"10","key":"5802_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","volume":"29","author":"M Hiligsmann","year":"2011","unstructured":"Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29(10):895\u2013911","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"5802_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108\u2013112","journal-title":"Osteoporos Int"},{"issue":"5","key":"5802_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone. 32(5):468\u2013473","journal-title":"Bone."},{"key":"5802_CR26","doi-asserted-by":"crossref","unstructured":"Piscitelli P, Neglia C, Feola M, Rizzo E, Argentiero A, Ascolese M, et al (2020) Updated incidence and costs of hip fractures in elderly Italian population. Aging Clin Exp Res 32:2587\u20132593","DOI":"10.1007\/s40520-020-01497-0"},{"issue":"9","key":"5802_CR27","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00198-019-05064-w","volume":"30","author":"A Svedbom","year":"2019","unstructured":"Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B (2019) Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporos Int 30(9):1745\u20131754","journal-title":"Osteoporos Int"},{"issue":"2","key":"5802_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32(2):198\u2013202","journal-title":"J Bone Miner Res"},{"key":"5802_CR29","doi-asserted-by":"crossref","unstructured":"Svedbom A, Borgstom F, Hernlund E, Strom O, Alekna V, Bianchi ML et al (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 29:557\u2013566","DOI":"10.1007\/s00198-017-4317-4"},{"issue":"4","key":"5802_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","volume":"82","author":"M Hiligsmann","year":"2008","unstructured":"Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82(4):288\u2013292","journal-title":"Calcif Tissue Int"},{"key":"5802_CR31","unstructured":"NICE 2020. Bisphosphonates for treating osteoporosis. Technology appraisal guidance. Last update 8 July 2019. Access on March 2020 from https:\/\/www.nice.org.uk\/guidance\/ta464\/resources\/bisphosphonates-for-treating-osteoporosis-pdf-82604905556677"},{"issue":"1","key":"5802_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00198-014-2900-5","volume":"26","author":"O Strom","year":"2015","unstructured":"Strom O, Landfeldt E, Garellick G (2015) Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 26(1):315\u2013325","journal-title":"Osteoporos Int"},{"issue":"8","key":"5802_CR33","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"key":"5802_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 105:11\u201317","journal-title":"Bone."},{"issue":"5","key":"5802_CR35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jval.2012.02.001","volume":"15","author":"M Hiligsmann","year":"2012","unstructured":"Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15(5):604\u2013612","journal-title":"Value Health"},{"issue":"2","key":"5802_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.healthpol.2010.01.014","volume":"96","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96(2):170\u2013177","journal-title":"Health Policy"},{"issue":"2","key":"5802_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1586\/erp.12.8","volume":"12","author":"M Hiligsmann","year":"2012","unstructured":"Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12(2):159\u2013166","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"5802_CR38","unstructured":"Giusti A, Bianchi G, Barone A, Black DM A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. Aging Clin Exp Res"},{"issue":"1","key":"5802_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00198-014-2871-6","volume":"26","author":"SL Silverman","year":"2015","unstructured":"Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C (2015) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 26(1):361\u2013372","journal-title":"Osteoporos Int"},{"key":"5802_CR40","doi-asserted-by":"crossref","unstructured":"Tremblay E, Perreault S, Dorais M (2016) Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos 11(1):30","DOI":"10.1007\/s11657-016-0282-3"},{"issue":"11","key":"5802_CR41","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D et al (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31(11):2093\u20132102","journal-title":"Osteoporos Int"},{"issue":"4","key":"5802_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9(4):e027049","journal-title":"BMJ Open"},{"issue":"10","key":"5802_CR43","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00198-006-0107-0","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17(10):1459\u20131471","journal-title":"Osteoporos Int"},{"issue":"11","key":"5802_CR44","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00198-011-1869-6","volume":"23","author":"K Lippuner","year":"2012","unstructured":"Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int 23(11):2579\u20132589","journal-title":"Osteoporos Int"},{"issue":"11","key":"5802_CR45","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention Trial (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"5802_CR46","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809\u20131822","journal-title":"N Engl J Med"},{"issue":"6","key":"5802_CR47","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Torring O et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96(6):1727\u20131736","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"5802_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344","journal-title":"Osteoporos Int"},{"issue":"1","key":"5802_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00198-011-1796-6","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 23(1):213\u2013221","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05802-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05802-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05802-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T14:03:56Z","timestamp":1667052236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05802-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["5802"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05802-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"24 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MH has received research grant support (all through institution) from Amgen, Bayer, Radius Health, ViiV Healthcare and Interface Science & Research, and lecture fees from Teva. JYR has received consulting fees or paid advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Teva; lecture fees when speaking at the invitation of sponsor: IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council, Teva; grant support from industry (all through institution) from IBSA-Genevrier, Mylan, CNIEL, Radius Health. SM has received grants from Sanofi Pasteur, MSD, GSK, Pfizer, Takeda for taking part to advisory boards, expert meetings, for acting as speaker and (through institution) as organizer of meetings\/congresses and as principal investigator of epidemiological studies.. The other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}